Efficacy, Immunogenicity and Safety Study Evaluating a Fractional (Fx) Booster Dose of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Latest Information Update: 06 Oct 2021
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Acronyms CHMI Booster Study
- Sponsors GlaxoSmithKline
Most Recent Events
- 27 Sep 2021 Results of this follow-on extension study assessing fractional booster vaccination extended or induced protection in previously protected or non-protected participants published in the Vaccine
- 03 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2019 Planned number of patients changed from 64 to 90.